Unified Patent Court (UPC) analytics are now available. Check here

TechnologyPatent OppositionCompetitive Analysis

In the competitive field of Pain And Inflammation Drugs, companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top opposing and opposed companies, and the most recent patents getting opposed. Stay informed on the latest developments in Pain And Inflammation Drugs technology and learn how to protect your intellectual property.

Get Patent Opposition Report for Pain And Inflammation Drugs

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the Pain And Inflammation Drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the Pain And Inflammation Drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the Pain And Inflammation Drugs industry

EP3038611Novel 2,4-Dinitrophenol Formulations And Methods Using SameYALE UNIVERSITYJan 17, 2025MITO PHARMACEUTICALS
EP3866765Injectable Long-Acting Naltrexone Microparticle CompositionsCHONG KUN DANG PHARMACEUTICALNov 6, 2024ALKERMES PHARMA IRELAND
EP3595667Pharmaceutical Compositions Comprising A Jak InhibitorALFASIGMASep 20, 2024ZAKLADY FARMACEUTYCZNE POLPHARMA
EP3595667Pharmaceutical Compositions Comprising A Jak InhibitorGALAPAGOSSep 17, 2024TEVA PHARMACEUTICAL INDUSTRIES
EP3862003An Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Disorder In Feline AnimalsBOEHRINGER INGELHEIM VETMEDICAJul 24, 2024ELANCO
EP4142703Compound And Composition For Inducing NeuroprotectionECOLE PRATIQUE DES HAUTES ETUDESJul 16, 2024BELHADJ TAHAR HAFID
EP3866615Human Dietary Supplement And Method For Treating Digestive System And Immune-Related DisordersFREEDOM HEALTHMay 30, 2024NUTRICIA
EP4028021Use Of Nmn For The Prevention And/Or Treatment Of Pain, And Corresponding CompositionsNUVAMIDMay 30, 2024SCHLICH
EP4084799Use Of Nmn For The Prevention And/Or Treatment Of Joint Pain Induced By Physical Activity, And Corresponding CompositionsNUVAMIDMay 30, 2024SCHLICH
EP4106757Methods Involving Neutrophil Elastase Inhibitor Alvelestat For Treating Respiratory Disease Mediated By Alpha-1 Antitrypsin DeficiencyMEREO BIOPHARMAMay 23, 2024ELKINGTON AND FIFE

To stay ahead in the competitive Pain And Inflammation Drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the Pain And Inflammation Drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Patent NumberGrant DateTitleApplicantTotal Oppositions
EP3078667Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA11
EP2397142Jul 27, 2022Use Of Dpp Iv InhibitorsBOEHRINGER INGELHEIM PHARMA5
EP2223688May 29, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofAMGEN EUROPE5
EP3241550Jul 22, 2020(1R, 2R)-3-(Dimenthyl Amino-1-Ethyl-2-Methyl-Propyl) Phenol For Treating Painful InflammationsGRNENTHAL4
EP2797581May 6, 2020Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPE3
EP3595667Dec 20, 2023Pharmaceutical Compositions Comprising A Jak InhibitorALFASIGMA3
EP2214679Mar 27, 2019Corticosteroid CompositionsMERITAGE PHARMA2
EP2849754Sep 14, 2022A Xanthine Derivative As Dpp-4 Inhibitor For Use In The Treatment Of Sirs And/Or SepsisBOEHRINGER INGELHEIM2
EP2305711Aug 2, 2017Methods For Treating Osteoarthitis Pain By Administering A Nerve Growth Factor Antagonist And Compositions Containing The SameRINAT NEUROSCIENCE2
EP2356914Dec 9, 2020Composition For Improving Membrane Composition And Functioning Of CellsNUTRICIA2